Everything your body does — how it makes energy, handles nutrients, manages inflammation, clears what it needs to clear, responds to medication — runs on a set of instructions you were born with.
A medical-grade genomic analysis reads those instructions. It is the deepest look at your biology available, and read by a physician it changes what your plan should be.
Reviewed by Dr. David Oliak, board-certified surgeon
Updated August 2026
Your labs describe what your body is doing right now. Your genes describe how it was built to do it.
That is a different order of information, and there is nothing beneath it. Every process a comprehensive panel measures — glucose handling, lipid metabolism, inflammation, the way you use vitamins — is downstream of instructions written before you were born. This reads the instructions.
For anyone interested in how their own body works, it is the most complete answer available.
A medical-grade analysis looks across the systems that determine how your body actually runs, and reports the variants within them that can change what a clinician does.
Nutrition. How efficiently you absorb, convert and use particular vitamins and minerals. This is often the most immediately useful part of a report, because it means the standard dose and the standard form are the wrong ones for you.
Inflammation and detoxification. How readily your system generates inflammation and along which pathways, and how well it clears what it needs to clear. Both sit underneath a wide range of symptoms and neither is usually investigated directly.
Gut health. Inherited factors in digestion, tolerance and the gut environment: territory that explains a great deal and is otherwise difficult to get at.
Cardiometabolic. How you handle fats, glucose and blood pressure. The same ground your panel covers, read at the level of why rather than what.
Brain, cognition and mood.
Medication response. How you metabolise particular drug classes. This explains reactions and failed trials from your past, and it informs a prescription before you take it rather than after.
That is not the whole of a report. It is the part that tends to change something.
The case for a comprehensive panel is that it measures change earlier than a standard one. The blueprint extends that argument as far as it goes.
A lab result, however early, is still a measurement of something that has already begun. Your genome is readable at any age, and it describes tendencies that were in place before anything started.
That is the difference between finding a process underway and knowing which processes you are predisposed to in the first place. Knowing that changes what is worth watching, what is worth correcting now, and what is worth treating earlier than a standard risk calculation would suggest.
In practice, reports routinely contain findings that change the plan.
Doses and forms. A variant affecting how you use a nutrient means the standard dose is the wrong dose for you, and often that a different form is the right one.
Medication choices. Knowing how you metabolise a drug class before prescribing is among the most immediately practical things genomics offers, and it is the part with the least ambiguity.
Where to intervene earlier. An inherited tendency can make an otherwise ordinary risk worth treating sooner than a population-based guideline would suggest.
Answers to things that never resolved. This is the one patients notice most. When something has persisted despite reasonable treatment, the explanation is sometimes a root cause that standard testing does not look for. And once you can see it, you can address it.
Care stops being what tends to work and becomes what works for you.
Genomics is the deepest read of a person we can get. It consistently produces things we would not otherwise have known — a nutrient handled poorly, a drug class to avoid, a pathway that explains a symptom that never made sense.
It does not replace judgement. That is why we read it alongside your labs and your history rather than handing over a file. But for someone who wants to understand how their own body actually works and act on it, there is nothing deeper available.
— Dr. David Oliak, board-certified physician and surgeon
Representative rather than exhaustive — a full report covers more ground than this.
The most common question, and the difference is substantial.
What is analysed. Consumer kits are built around ancestry, with health as a secondary output. A clinical platform selects variants for their relevance to medical decisions.
Who reads it. A consumer report is generated by an algorithm and sent to you. Yours is read by your own physician, next to your labs, your history and your symptoms.
What comes out. A consumer report ends in information. A clinical one ends in a plan.
The platform we use is IntellxxDNA, a medical-grade system built for clinicians and designed to be interpreted by a physician rather than handed over as raw data.
One sample, once. A simple collection, done a single time. Your genome does not change, so it never needs repeating — and it remains useful for the rest of your life.
Two in-depth visits. The report covers a great deal, and the parts that matter to you deserve a real conversation rather than the last ten minutes of another appointment.
Built into your plan. The findings sit alongside your labs, and one plan comes out of both.
At your pace. What you choose to look at is your decision, discussed before anything is ordered.
Two kinds of people, mostly.
People who want the data. No particular complaint — an interest in understanding how their own body works, and a preference for acting on their own information rather than on averages. For them this is simply the most complete answer available, and a one-time thing that stays useful for the rest of their life.
People with something unresolved. A symptom that has persisted through reasonable treatment, or a pattern nobody has been able to explain. When the standard workup has been unremarkable and the problem has not gone away, a deeper read is often where the explanation turns out to be.
Where it tends to matter most. Three areas come up repeatedly. Mental health, where how you metabolise a medication often explains why one worked and another did not, and where the pathways involved are rarely examined directly. Inflammatory problems, where the tendency is inherited and sits underneath a wide range of symptoms. And long-term risk, where knowing what you are predisposed to allows risk to be stratified against your own biology rather than against population averages — and acted on early enough to change the trajectory rather than manage the outcome.
It is a significant investment and it is not part of the evaluation by default. Most people begin with the comprehensive panel and add the blueprint when they want to go further — which is a perfectly good order to do it in.
Two things define what the blueprint is good for and what it is not.
It describes predispositions, not certainties. Genes are one contributor alongside how you live and what you are exposed to. A strong tendency is a reason to act, not a verdict.
It is insight a physician acts on, not a diagnosis. The value is in what it changes about your care, which is why it is read with everything else we know about you.
Your genetic information is kept confidential and used to inform your care.
Federal law — the Genetic Information Nondiscrimination Act — prohibits health insurers and employers from using genetic information to discriminate against you. That protection does not extend to every kind of insurance, which is worth knowing beforehand and is part of the conversation before anything is ordered.
Let's begin
The blueprint is an option within the comprehensive evaluation — read by your physician, alongside your labs, and built into one plan. In Brea. To speak with us first, call 714-671-2005.
What a comprehensive blood panel measures
Fasting insulin: the marker most panels skip
ApoB and Lp(a): better measures of cardiovascular risk
Supplements: what's actually worth taking
A medical-grade genomic analysis, read by your physician and built into your plan. It covers how you handle nutrients, how your system manages inflammation and detoxification, inherited cardiometabolic factors, brain and cognitive health, and how you metabolise particular medications.
Commonly: the dose and form of a nutrient, because you handle it differently from the average; which medications suit you, before you try them. Commonly, too: where a tendency makes it worth intervening earlier than a general guideline would suggest; and sometimes the explanation for a symptom that never resolved despite reasonable treatment.
Those are built around ancestry, generated by an algorithm, and delivered to you. This is a clinical platform focused on variants that change care, read by your own physician alongside your labs and history, and turned into a plan.
It describes predispositions rather than certainties. Genes are one contributor alongside how you live and what you are exposed to. A strong tendency is a reason to act on something now — which is more useful than a prediction would be.
A lab result measures something already underway, however early. Your genome describes tendencies that were in place before anything started, and it can be read at any age.
Once. Your genome does not change, so a single test serves for life.
No. What you choose to learn is your decision, discussed before anything is ordered.
Yes. It is kept confidential and used only to inform your care. Federal law prohibits health insurers and employers from using genetic information to discriminate against you, though that protection does not extend to every kind of insurance — part of the conversation beforehand.
It is priced separately from the evaluation and depends on the panel chosen. The Comprehensive Evaluation page has current figures.
